 Purpose: In an open-label randomized phase II trial, patients with metastatic Human Epidermal Growth Factor Receptor 2-negative breast cancer with normal organ function sant WHO performance status 3 are randomized to receive either capecitabine day 1-14 plus vinorelbine oral day 1 and 8 or capecitabine day 1-14 plus vinorelbine oral metronomic 3 days a week. 